New Insights to Cancer Therapy Resistance
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 3150
Special Issue Editor
Interests: DNA repair; immune response; cancer therapy; software tools; molecular biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, considerable advances have been made in understanding tumor-driving mechanisms, which have fueled the development of novel therapeutic approaches benefitting many patients. The major progress is represented by the further development of immunotherapy and targeted therapy with small molecules, e.g., KRASG12C-specific inhibitors. Despite this considerable progress, cancer is an evolving disease, and resistance develops almost immediately and is found in clinics.
The current Special Issue addresses the emerging questions of how these forms of resistance occur and reveal the underlying mechanisms. The collation of more detailed knowledge obtained from experts of different cancer research fields addressing the relationships of molecular mechanisms and resistances occurring in clinics offers a great opportunity to promote an improved understanding and the development of resistance-overcoming approaches.
Dr. Sebastian Oeck
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- resistance
- molecular mechanisms
- clinical approaches
- novel therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
